Zitcop Gel is a topical formulation containing Clindamycin 1% w/w and Nicotinamide 4% w/w, indicated for the treatment of acne vulgaris. Clindamycin, a lincosamide antibiotic, exerts its therapeutic effect by inhibiting bacterial protein synthesis, thereby targeting Propionibacterium acnes, a key pathogen involved in acne pathogenesis. Nicotinamide, a form of vitamin B3, possesses anti-inflammatory and sebostatic properties, contributing to the reduction of erythema, inflammation, and sebum production associated with acne lesions. The combination of these active ingredients provides a dual mechanism of action, addressing both bacterial colonization and inflammatory processes. Zitcop Gel is applied topically to the affected areas once or twice daily as directed by a healthcare professional. It is generally well tolerated, with minimal systemic absorption, reducing the risk of systemic side effects. Common local adverse reactions may include mild irritation, dryness, or erythema at the application site, which are usually transient. The use of Zitcop Gel should be avoided in individuals with known hypersensitivity to clindamycin, nicotinamide, or any component of the formulation. Patients are advised to avoid contact with eyes, mucous membranes, and broken skin. Consistent use as prescribed is essential for optimal therapeutic outcomes in acne management.